Kana Miyata

Kana Miyata practices at SSM Health Saint Louis University Hospital in Saint Louis, Missouri, part of SSM Health Care.

Kana Miyata's NPI, 1205114477, was assigned on July 21, 2011. Kana Miyata holds Missouri license 2020016492.

Kana Miyata's primary practice is SSM Health Saint Louis University Hospital, at 1201 S Grand Blvd, Saint Louis, MO 63104 in St. Louis City. The practice phone is (314) 257-8000.

Kana Miyata's primary practice is SSM Health Saint Louis University Hospital in Saint Louis, Missouri, part of SSM Health Care. The medical group on file is SLUCare Physician Group. Dmand AI also links Kana Miyata to 1 more behavioral health center, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kana Miyata practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Kana Miyata's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Kana Miyata's licenses on file in 2 states: Missouri and California.

CMS data shows 235 Medicare services from Kana Miyata across 6 procedure codes in 2024, for 85 Medicare patients. Medicare paid $18,878 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 85 Medicare patients who saw Kana Miyata in 2024. The largest group is 65 to 74, with 37 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 53% are also on Medicaid. Their average risk score is 6.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Kana Miyata's median patient age at 70, with 52% women.

In 2024, Kana Miyata wrote 367 Medicare Part D claims for 59 patients. 78% of them were for generic drugs. CMS names the drug for 248 of them, across 10 drugs with 11 or more claims each, at $51,303 in total drug cost. In 2023, CMS named 167 claims across 7 drugs.

Kana Miyata accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 29 papers to Kana Miyata, published from 2014 to 2025. 2021 was the busiest year, with 3. The most frequent topics are Mice, Knockout, Sodium-Glucose Transporter 2 Inhibitors and Diabetes Mellitus, Type 1. Kana Miyata has published most often in Transl Res. Kana Miyata's most frequent co-authors are Julie R. Ingelfinger, MD, Yasar Kerem Caliskan, MD and Krista L. Lentine, MD, PhD.

CMS Open Payments shows 27 general payments to Kana Miyata from 13 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 69% of the total. Travere Therapeutics, Inc. paid the most, $1,129.